Dr. Goldsmith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1405 Clifton Rd NE
Atlanta, GA 30322Phone+1 404-785-1112Fax+1 404-785-6288
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2002 - 2005- Children's Hospital of PhiladelphiaResidency, Pediatrics, 1999 - 2002
University of Alabama School of MedicineClass of 1999
Certifications & Licensure
GA State Medical License 2009 - 2025
PA State Medical License 2000 - 2010- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01
- MIBG With Dinutuximab +/- Vorinostat Start of enrollment: 2018 Sep 12
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- 26 citationsA 3D Bioprinted in vitro Model of Neuroblastoma Recapitulates Dynamic Tumor-Endothelial Cell Interactions Contributing to Solid Tumor Aggressive Behavior.Liqun Ning, Jenny Shim, Martin L Tomov, Rui Liu, Riya Mehta
Advanced Science. 2022-08-01 - 11 citationsReduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance.Jorida Çoku, David M Booth, Jan Skoda, Madison C Pedrotty, Jennifer Vogel
The EMBO Journal. 2022-04-19 - 6 citationsComprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.Ryan J Summers, Sharon M Castellino, Christopher C Porter, Tobey J MacDonald, Gargi D Basu
JCO Precision Oncology. 2022-04-01
Press Mentions
- Clinical Trial May Change the Paradigm of Care for Patients with ALK-Driven High-Risk NeuroblastomaApril 4th, 2023
- Researchers Show Lorlatinib Is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk NeuroblastomaMarch 31st, 2023
- Targeted Cancer Treatment Helps Georgia Boy Facing Advanced NeuroblastomaOctober 5th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
